latest news releases from the newsroom
World Golf League, Inc.
The World Golf League Launches Telemarketing Program
ORLANDO, Fla., March 31, 2004 (PRIMEZONE) -- The World Golf League, Inc. (OTCBB:WGFL) announced today that it has started its membership Telemarketing Program on March 28, 2004. The program is concentrating on the 10 most popular states based on the response patterns of the television media campaign. Call Solutions of Fort Worth, Texas has staffed an outbound call center in Florida, which will have the capacity to grow to 100 agents dedicated to the WGL program. The center will operate five days per week and 8 hours per day. In addition, Call Solutions will staff an inbound call center to handle all of the WGL inbound traffic beginning April 5, 2004.
Scania Annual Report 2003
STOCKHOLM, Sweden, March 31, 2004 (PRIMEZONE) -- Today the distribution starts of the Scania Annual Report 2003. The report is available on Scania's website http://www.scania.com/ir/Reports/annual.asp, in web and PDF formats both in Swedish and English.
Elekta Receives Regulatory Approval in Japan For Latest Model of Leksell Gamma Knife
STOCKHOLM, Sweden, March 31, 2004 (PRIMEZONE) -- Earlier in March, Elekta was notified that the Japanese Ministry for Health, Labor and Welfare has granted approval for Leksell Gamma Knife(R) C 1.2, the latest version of the gold standard equipment for non-invasive intra-cranial radiosurgery. Elekta's customers in Japan will thereby be able to upgrade to the most advanced modality for treatment of brain tumors, vascular malformations and functional diseases.
Scania launches new truck range
SODERTALJE, Sweden, March 31, 2004 (PRIMEZONE) -- At a press conference today, Scania launches its new R-series, a range of long-haulage trucks that is an important extension of its global truck offer. The trucks feature innovations and improvements in many areas. Quality, operating economy, uptime and driver environment have been the principal focus areas during development. A new Euro 4 engine complies with forthcoming emission standards.
EU Patent Granted on Medivir's Herpes Project ME-609
HUDDINGE, Sweden, March 31, 2004 (PRIMEZONE) -- The European Patent Office today granted a patent on Medivir's herpes project ME-609. Medivir currently has operational responsibility for development of the project and preparations towards phase III studies are ongoing. The company's ambition is to have a "turn key" project ready for phase III studies. In parallel Medivir is actively seeking a partnership or joint venture for this advanced and for Medivir important project.
Volvo Trucks Inaugurates Factory in China
GOTEBORG, Sweden, March 31, 2004 (PRIMEZONE) -- Volvo Truck Corporation is today inaugurating a new factory in Jinan together with its Chinese partner, China National Heavy Truck Corporation (CNHTC). The new factory will build Volvo trucks for the growing Chinese market. The factory has initially a capacity of about 1,200 trucks a year.
CTT Receives Order for Cair for Airbus A330-200 and A340-500 VIPAircraft
STOCKHOLM, Sweden and HAMBURG, Germany, March 31, 2004 (PRIMEZONE) -- CTT Systems received, during the Hamburg Aircraft Interiors expo, an order for the CTT Cair(tm) System for one Airbus A330-200 VIP and one A340-500 VIP aircraft from a Middle East customer. The order is firm for two aircraft systems and with deliveries starting in mid 2004. Sogerma in Bourdeaux will complete the installation for the A340-500.
Celltech Group plc
Celltech Group plc Outlines Positive Preliminary Results From First CDP870 Phase III Trial In Rheumatoid Arthritis
SLOUGH, U.K., March 31, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces positive preliminary results from the first Phase III clinical trial with CDP870 in rheumatoid arthritis ("Study 014"). Study 014 was designed to assess the safety and efficacy of CDP870 in combination with methotrexate on signs and symptoms of disease over a six month period in a refractory group of patients, who had active moderate to severe disease despite treatment with methotrexate and other disease modifying anti-rheumatic drugs ("DMARDs").